Difference between revisions of "Week4"

From Pheno Wiki
Jump to: navigation, search
Line 70: Line 70:
  
 
[[Image:kd1.png | thumb |right | Putative endophenotypes of Late-Onset Alzheimer's Disease (Reitz et al., 2009) ]]
 
[[Image:kd1.png | thumb |right | Putative endophenotypes of Late-Onset Alzheimer's Disease (Reitz et al., 2009) ]]
 +
 +
  
 
*Methods
 
*Methods
Line 78: Line 80:
  
 
Participants were screened for cognitive decline with standardized neuropsychological testing, and evaluated biennially thereafter with the Folstein Mini Mental Status Exam. If this test, the participant, physician, or family raised the possibility of cognitive decline, more thorough neurological and neuropsychological testing was performed.  Data acquired through Decebmer of 2007 were used for this study.
 
Participants were screened for cognitive decline with standardized neuropsychological testing, and evaluated biennially thereafter with the Folstein Mini Mental Status Exam. If this test, the participant, physician, or family raised the possibility of cognitive decline, more thorough neurological and neuropsychological testing was performed.  Data acquired through Decebmer of 2007 were used for this study.
 +
  
  
 
*Results
 
*Results
 +
  
  
 
*Summary
 
*Summary
 +
 +
  
 
*Discussion
 
*Discussion

Revision as of 18:46, 20 January 2010

Back to NS210b Class page

MANUSCRIPT ID

  • Title
  • Reference
  • Abstract
  • Keywords
  • Input Author


MANUSCRIPT DETAILS

  • Introduction/Aims
  • Methods
  • Results
  • Summary
  • Discussion


MANUSCRIPT ID

  • Title

Association of plasma leptin levels with incident Alzheimer disease and MRI measures of brain aging.


  • Reference

JAMA. 2009 Dec 16;302(23):2565-72.


  • Abstract

CONTEXT: The adipokine leptin facilitates long-term potentiation and synaptic plasticity in the hippocampus, promotes beta-amyloid clearance, and improves memory function in animal models of aging and Alzheimer disease (AD). OBJECTIVE: To relate baseline circulating leptin concentrations in a community-based sample of individuals without dementia to incident dementia and AD during follow-up and magnetic resonance imaging (MRI) measures of brain aging in survivors. DESIGN, SETTING, AND PARTICIPANTS: Prospective study of plasma leptin concentrations measured in 785 persons without dementia (mean [SD] age, 79 [5] years; 62% female), who were in the Framingham original cohort at the 22nd examination cycle (1990-1994). A subsample of 198 dementia-free survivors underwent volumetric brain MRI between 1999 and 2005, approximately 7.7 years after leptin was assayed. Two measures of brain aging, total cerebral brain volume and temporal horn volume (which is inversely related to hippocampal volume) were assessed. MAIN OUTCOME MEASURE: Incidence of dementia and AD during follow-up until December 31, 2007. RESULTS: During a median follow-up of 8.3 years (range, 0-15.5 years), 111 participants developed incident dementia; 89 had AD. Higher leptin levels were associated with a lower risk of incident dementia and AD in multivariable models (hazard ratio per 1-SD increment in log leptin was 0.68 [95% confidence interval, 0.54-0.87] for all-cause dementia and 0.60 [95% confidence interval, 0.46-0.79] for AD). This corresponds to an absolute AD risk over a 12-year follow-up of 25% for persons in the lowest quartile (first quartile) vs 6% for persons in the fourth quartile of sex-specific leptin levels. In addition, a 1-SD elevation in plasma leptin level was associated with higher total cerebral brain volume and lower temporal horn volume, although the association of leptin level with temporal horn volume did not reach statistical significance. CONCLUSION: Circulating leptin was associated with a reduced incidence of dementia and AD and with cerebral brain volume in asymptomatic older adults.


  • Keywords

Alzheimer's disease, leptin, metabolism, aging, brain volume


  • Input Author

KCO


MANUSCRIPT DETAILS

  • Introduction/Aims

Obesity and insulin resistance have been identified as risk factors for Alzheimer's disease, and prospective studies have shown that mid-life obesity is associated with increased risk of dementia and poorer cognitive function in the general population.

Leptin is an adipokine with a role in the regulation of signaling caloric intake and fat stores to the hypothalamus. This signaling alters food consumption, with high levels of leptin indicating satiety.

More recently, a role of leptin in memory facilitation has been identified. In addition to its role in the hypothalamus, leptin has been shown to act in the CA1 region of the hippocampus, and mice with defective leptin receptors show diminished long-term potentiation and poorer performance on memory tasks.

Changes in brain morphology have been suggested as putative endophenotypes of Alzheimer's disease (see figure, from Reitz et al., 2009)[1]. This study uses data from participants who underwent structural MRI to investigate the relationship between brain volume and dementia.

In this study, researchers aimed to relate baseline plasma leptin levels in individuals free of dementia to the later incidence of dementia and Alzheimer's disease, and to relate those results to the morphological appearance of the brain.

Putative endophenotypes of Late-Onset Alzheimer's Disease (Reitz et al., 2009)


  • Methods

Participants were part of the Framingham Heart Study [2] initiated in 1948. Leptin levels were measured in 785 participants without dementia in the twenty-second examination cycle (1990-1994).

Of those individuals, 198 underwent volumetric MRI between 1999 and 2005. These data were also used in another study (DeCarli et al, Neurobiol Aging. 2005;26(4):491-510)[3]. For the purposes of the 2009 study, the morphometric characteristics evaluated were total cerebral brain volume and temporal horn volume.

Participants were screened for cognitive decline with standardized neuropsychological testing, and evaluated biennially thereafter with the Folstein Mini Mental Status Exam. If this test, the participant, physician, or family raised the possibility of cognitive decline, more thorough neurological and neuropsychological testing was performed. Data acquired through Decebmer of 2007 were used for this study.


  • Results


  • Summary


  • Discussion